UMF
Cluj-Napoca, Romania
UMF
Cluj-Napoca, Romania

Time filter

Source Type

News Article | May 23, 2017
Site: globenewswire.com

BOULDER, Colo., May 23, 2017 (GLOBE NEWSWIRE) -- UMF Group Inc. (OTC Pink:UMFG) (“the Company”) is pleased to provide a corporate update exemplifying a change in the direction of the business from Oil and Gas Exploration to Medical Marijuana. UMF Group Inc. would like to welcome Nicole Merion, Director of Business Development, to the company. Nicole Merion brings a wealth of scientific knowledge and contacts at the highest levels of academia and production, facilitating UMF Group Inc.’s vision of operating at the cutting edge of technology and research. She also brings a history of production and development to the company and has been working in the Cannabis field for the past ten years. The company has shifted to an innovative Medical Marijuana company, which aims to develop and approve proprietary extracts as pharmaceuticals, and to ultimately deliver to the market pharmaceuticals that are highly differentiated both from medical marijuana and from current cannabinoid drugs. UMF Group Inc. maintains a proprietary “whole plant” method of extracting various cannabinoids from the marijuana plant and converting them into higher quality and quantity. Several important events have led to the opportunity of a lifetime for Cannabis Cultivators and Industry Innovators. UMF Group Inc. is poised to make significant strides in the years to come. The US medical cannabis market generated $6.7 billion in sales in 2016, with sales expected to grow to $21.8 billion by 2020. Due to the rapidly changing American situation, with recent favorable legislative changes, in the US, medical cannabis is now legal in 28 states. The opportunity for market capitalization is not limited to America. Global legal cannabis markets are expected to grow to $140.5 billion in 2020 from $28.8 billion in 2015 according to global market firm Technavio. The Medical Marijuana industry is about to go global and UMF Group Inc. is positioned to be a market leader. FORWARD LOOKING STATEMENT This news release includes forward-looking statements that reflect UMF Group Inc. current expectations about its future results, performance, prospects and opportunities UMF Group Inc. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to UMF Group Inc. and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities in the remainder of 2017 and beyond, to differ materially from those expressed in, or implied by, these forward-looking statements.


News Article | May 23, 2017
Site: globenewswire.com

BOULDER, Colo., May 23, 2017 (GLOBE NEWSWIRE) -- UMF Group Inc. (OTC Pink:UMFG) (“the Company”) is pleased to provide a corporate update exemplifying a change in the direction of the business from Oil and Gas Exploration to Medical Marijuana. UMF Group Inc. would like to welcome Nicole Merion, Director of Business Development, to the company. Nicole Merion brings a wealth of scientific knowledge and contacts at the highest levels of academia and production, facilitating UMF Group Inc.’s vision of operating at the cutting edge of technology and research. She also brings a history of production and development to the company and has been working in the Cannabis field for the past ten years. The company has shifted to an innovative Medical Marijuana company, which aims to develop and approve proprietary extracts as pharmaceuticals, and to ultimately deliver to the market pharmaceuticals that are highly differentiated both from medical marijuana and from current cannabinoid drugs. UMF Group Inc. maintains a proprietary “whole plant” method of extracting various cannabinoids from the marijuana plant and converting them into higher quality and quantity. Several important events have led to the opportunity of a lifetime for Cannabis Cultivators and Industry Innovators. UMF Group Inc. is poised to make significant strides in the years to come. The US medical cannabis market generated $6.7 billion in sales in 2016, with sales expected to grow to $21.8 billion by 2020. Due to the rapidly changing American situation, with recent favorable legislative changes, in the US, medical cannabis is now legal in 28 states. The opportunity for market capitalization is not limited to America. Global legal cannabis markets are expected to grow to $140.5 billion in 2020 from $28.8 billion in 2015 according to global market firm Technavio. The Medical Marijuana industry is about to go global and UMF Group Inc. is positioned to be a market leader. FORWARD LOOKING STATEMENT This news release includes forward-looking statements that reflect UMF Group Inc. current expectations about its future results, performance, prospects and opportunities UMF Group Inc. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to UMF Group Inc. and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities in the remainder of 2017 and beyond, to differ materially from those expressed in, or implied by, these forward-looking statements.


News Article | May 23, 2017
Site: globenewswire.com

BOULDER, Colo., May 23, 2017 (GLOBE NEWSWIRE) -- UMF Group Inc. (OTC Pink:UMFG) (“the Company”) is pleased to provide a corporate update exemplifying a change in the direction of the business from Oil and Gas Exploration to Medical Marijuana. UMF Group Inc. would like to welcome Nicole Merion, Director of Business Development, to the company. Nicole Merion brings a wealth of scientific knowledge and contacts at the highest levels of academia and production, facilitating UMF Group Inc.’s vision of operating at the cutting edge of technology and research. She also brings a history of production and development to the company and has been working in the Cannabis field for the past ten years. The company has shifted to an innovative Medical Marijuana company, which aims to develop and approve proprietary extracts as pharmaceuticals, and to ultimately deliver to the market pharmaceuticals that are highly differentiated both from medical marijuana and from current cannabinoid drugs. UMF Group Inc. maintains a proprietary “whole plant” method of extracting various cannabinoids from the marijuana plant and converting them into higher quality and quantity. Several important events have led to the opportunity of a lifetime for Cannabis Cultivators and Industry Innovators. UMF Group Inc. is poised to make significant strides in the years to come. The US medical cannabis market generated $6.7 billion in sales in 2016, with sales expected to grow to $21.8 billion by 2020. Due to the rapidly changing American situation, with recent favorable legislative changes, in the US, medical cannabis is now legal in 28 states. The opportunity for market capitalization is not limited to America. Global legal cannabis markets are expected to grow to $140.5 billion in 2020 from $28.8 billion in 2015 according to global market firm Technavio. The Medical Marijuana industry is about to go global and UMF Group Inc. is positioned to be a market leader. FORWARD LOOKING STATEMENT This news release includes forward-looking statements that reflect UMF Group Inc. current expectations about its future results, performance, prospects and opportunities UMF Group Inc. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to UMF Group Inc. and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities in the remainder of 2017 and beyond, to differ materially from those expressed in, or implied by, these forward-looking statements.


News Article | May 30, 2017
Site: globenewswire.com

BOULDER, Colo., May 30, 2017 (GLOBE NEWSWIRE) -- UMF Group Inc. (UMFG) (OTC Pink:UMFG) (“the Company”) is pleased to announce the launch of a corporate website. As our society is becoming more digital based, it is necessary to have a predominant presence on the Internet.  UMF Group Inc.’s newly launched corporate website www.umfgroupinc.com is an efficient, and effective marketing tool and an improved visitor experience. By continuing to add high quality content will enable our search engine rankings to improve as well as branding, generating greater sales, and improved customer loyalty. The company also benefits from reduced operating costs such as rents, rates and labor and are thus able to pass these savings on to the consumer. Central access to otherwise decentralized, retained information and the option to personalize content for target user groups will provide the right type of information supporting the client in their research and purchase of our proprietary whole plant extraction products.  Whole-Plant Cannabis concentrates has become the “Gold Standard”, according to Medical Jane (an online educational resource for patients, caregivers, and health care professionals in the legal cannabis industry). Patients are reporting incredible success stories from whole-plant extracts, these patients typically use whole-plant concentrates in the form of RSO, tinctures, solvent-less wax, and more. FORWARD LOOKING STATEMENT This news release includes forward-looking statements that reflect UMF Group Inc. current expectations about its future results, performance, prospects and opportunities UMF Group Inc. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to UMF Group Inc. and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities in the remainder of 2017 and beyond, to differ materially from those expressed in, or implied by, these forward-looking statements.


News Article | May 30, 2017
Site: globenewswire.com

BOULDER, Colo., May 30, 2017 (GLOBE NEWSWIRE) -- UMF Group Inc. (UMFG) (OTC Pink:UMFG) (“the Company”) is pleased to announce the launch of a corporate website. As our society is becoming more digital based, it is necessary to have a predominant presence on the Internet.  UMF Group Inc.’s newly launched corporate website www.umfgroupinc.com is an efficient, and effective marketing tool and an improved visitor experience. By continuing to add high quality content will enable our search engine rankings to improve as well as branding, generating greater sales, and improved customer loyalty. The company also benefits from reduced operating costs such as rents, rates and labor and are thus able to pass these savings on to the consumer. Central access to otherwise decentralized, retained information and the option to personalize content for target user groups will provide the right type of information supporting the client in their research and purchase of our proprietary whole plant extraction products.  Whole-Plant Cannabis concentrates has become the “Gold Standard”, according to Medical Jane (an online educational resource for patients, caregivers, and health care professionals in the legal cannabis industry). Patients are reporting incredible success stories from whole-plant extracts, these patients typically use whole-plant concentrates in the form of RSO, tinctures, solvent-less wax, and more. FORWARD LOOKING STATEMENT This news release includes forward-looking statements that reflect UMF Group Inc. current expectations about its future results, performance, prospects and opportunities UMF Group Inc. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to UMF Group Inc. and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities in the remainder of 2017 and beyond, to differ materially from those expressed in, or implied by, these forward-looking statements.


News Article | May 30, 2017
Site: globenewswire.com

BOULDER, Colo., May 30, 2017 (GLOBE NEWSWIRE) -- UMF Group Inc. (UMFG) (OTC Pink:UMFG) (“the Company”) is pleased to announce the launch of a corporate website. As our society is becoming more digital based, it is necessary to have a predominant presence on the Internet.  UMF Group Inc.’s newly launched corporate website www.umfgroupinc.com is an efficient, and effective marketing tool and an improved visitor experience. By continuing to add high quality content will enable our search engine rankings to improve as well as branding, generating greater sales, and improved customer loyalty. The company also benefits from reduced operating costs such as rents, rates and labor and are thus able to pass these savings on to the consumer. Central access to otherwise decentralized, retained information and the option to personalize content for target user groups will provide the right type of information supporting the client in their research and purchase of our proprietary whole plant extraction products.  Whole-Plant Cannabis concentrates has become the “Gold Standard”, according to Medical Jane (an online educational resource for patients, caregivers, and health care professionals in the legal cannabis industry). Patients are reporting incredible success stories from whole-plant extracts, these patients typically use whole-plant concentrates in the form of RSO, tinctures, solvent-less wax, and more. FORWARD LOOKING STATEMENT This news release includes forward-looking statements that reflect UMF Group Inc. current expectations about its future results, performance, prospects and opportunities UMF Group Inc. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to UMF Group Inc. and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities in the remainder of 2017 and beyond, to differ materially from those expressed in, or implied by, these forward-looking statements.


News Article | May 30, 2017
Site: globenewswire.com

BOULDER, Colo., May 30, 2017 (GLOBE NEWSWIRE) -- UMF Group Inc. (UMFG) (OTC Pink:UMFG) (“the Company”) is pleased to announce the launch of a corporate website. As our society is becoming more digital based, it is necessary to have a predominant presence on the Internet.  UMF Group Inc.’s newly launched corporate website www.umfgroupinc.com is an efficient, and effective marketing tool and an improved visitor experience. By continuing to add high quality content will enable our search engine rankings to improve as well as branding, generating greater sales, and improved customer loyalty. The company also benefits from reduced operating costs such as rents, rates and labor and are thus able to pass these savings on to the consumer. Central access to otherwise decentralized, retained information and the option to personalize content for target user groups will provide the right type of information supporting the client in their research and purchase of our proprietary whole plant extraction products.  Whole-Plant Cannabis concentrates has become the “Gold Standard”, according to Medical Jane (an online educational resource for patients, caregivers, and health care professionals in the legal cannabis industry). Patients are reporting incredible success stories from whole-plant extracts, these patients typically use whole-plant concentrates in the form of RSO, tinctures, solvent-less wax, and more. FORWARD LOOKING STATEMENT This news release includes forward-looking statements that reflect UMF Group Inc. current expectations about its future results, performance, prospects and opportunities UMF Group Inc. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to UMF Group Inc. and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities in the remainder of 2017 and beyond, to differ materially from those expressed in, or implied by, these forward-looking statements.


News Article | December 2, 2016
Site: www.newsmaker.com.au

This report studies ENT Chairs in Global Market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East and Africa,  focuses on the top Manufacturers in each country, covering  Atmos Medical  Heinemann Medizintechnik  Haag Streit  Optomic  Chammed  Global Surgical  BOKEER  Mega Medical  Nagashima Medical  Arsimed Medical  Innotech Medical  Olsen  Tecnodent  UMF Medical Market Segment by Countries, this report splits Global into several key Countries, with sales, revenue, market share of top players in these Countries, from 2012 to 2017 (forecast), like  1 United States  2 Canada  3 Mexico  4 Germany  5 France  6 UK  7 Italy  8 Russia  9 China  10 Japan  11 India  12 Korea  13 Southeast Asia  14 Australia  15 Brazil  16 Middle East  17 Africa Split by Product Types, with sales, revenue, price, market share of each type, can be divided into  Manual ENT Chairs  Powered ENT Chairs Split by applications, this report focuses on sales, market share and growth rate of ENT Chairs in each application, can be divided into  Hospitals  Clinics 2017-2022 Global Top Countries ENT Chairs Market Report  1 ENT Chairs Market Overview  1.1 Product Overview and Scope of ENT Chairs  1.2 ENT Chairs Segment by Types  1.2.1 Global Sales Market Share of ENT Chairs by Types in 2015  1.2.2 Manual ENT Chairs  1.2.3 Powered ENT Chairs  1.3 ENT Chairs Segment by Applications  1.3.1 ENT Chairs Consumption Market Share by Applications in 2015  1.3.2 Hospitals  1.3.3 Clinics  1.4 ENT Chairs Market by Countries  1.4.1 United States Status and Prospect (2012-2022)  1.4.2 Canada Status and Prospect (2012-2022)  1.4.3 Germany Status and Prospect (2012-2022)  1.4.4 France Status and Prospect (2012-2022)  1.4.5 UK Status and Prospect (2012-2022)  1.4.6 Italy Status and Prospect (2012-2022)  1.4.7 Russia Status and Prospect (2012-2022)  1.4.8 China Status and Prospect (2012-2022)  1.4.9 Japan Status and Prospect (2012-2022)  1.4.10 India Status and Prospect (2012-2022)  1.4.11 Korea Status and Prospect (2012-2022)  1.4.12 Southeast Asia Status and Prospect (2012-2022)  1.4.13 Australia Status and Prospect (2012-2022)  1.4.14 Brazil Status and Prospect (2012-2022)  1.4.15 Mexico Status and Prospect (2012-2022)  1.4.16 Middle East Status and Prospect (2012-2022)  1.4.17 Africa Status and Prospect (2012-2022)  1.5 Global ENT Chairs Overview and Market Size (Value) (2012-2022)  1.5.1 Global Market ENT Chairs Overview  1.5.2 Global Market ENT Chairs Revenue (Million USD) and Growth Rate (2012-2022)  2 Global ENT Chairs Sales, Revenue (Value) and Market Share by Manufacturers  2.1 Global ENT Chairs Sales and Market Share in 2015 and 2016 by Manufacturers  2.2 Global ENT Chairs Revenue and Market Share by Manufacturers in 2015 and 2016  2.3 Global ENT Chairs Average Price by Manufacturers in 2015 and 2016  2.4 Global ENT Chairs Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers  2.5 ENT Chairs Market Competitive Situation and Trends  2.5.1 ENT Chairs Market Concentration Rate  2.5.2 ENT Chairs Market Share of Top 3 and Top 5 Manufacturers  2.5.3 Mergers & Acquisitions, Expansion  3 Global ENT Chairs Sales, Revenue (Value) by Countries, Type and Application (2012-2017)  3.1 Global ENT Chairs Sales, Revenue and Market Share by Countries (2012-2017)  3.1.1 Global ENT Chairs Sales and Market Share by Countries (2012-2017)  3.1.2 Global ENT Chairs Revenue and Market Share by Countries (2012-2017)  3.1.3 Global ENT Chairs Price by Countries (2012-2017)  3.2 Global ENT Chairs Sales, Revenue, Market Share and Price by Type (2012-2017)  3.2.1 Global ENT Chairs Sales and Market Share by Type (2012-2017)  3.2.2 Global ENT Chairs Revenue and Market Share by Type (2012-2017)  3.2.3 Global ENT Chairs Price by Type (2012-2017)  3.3 Global ENT Chairs Sales and Market Share by Application (2012-2017)  3.4 Global Market ENT Chairs Sales, Revenue, Price and Gross Margin (2012-2017) For more information or any query mail at [email protected]


News Article | November 14, 2016
Site: www.marketwired.com

BROSSARD, QUEBEC--(Marketwired - Nov. 14, 2016) - Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, celebrates today the World Diabetes Day by announcing a pilot in partnership with Mexico's National Social Security System. The public-private partnership (PPP) for the pilot involves both sides commitments: from one side the Mexican Social Security Institute's (IMSS for Spanish) Head Office, Entailment Department, Department of Chief Medical Officer along with its several divisions: Special National Health Projects, Primary-Secondary-and Tertiary level of attention divisions, as well as the National Coordination of Ophthalmology; from the other side DIAGNOS' proprietary artificial intelligence Computer Assisted Retinal Analysis (CARA) and its Wellness Program: hardware, CARA platform and specialized staff in eye care to manage diabetics and operate our technology, IT Department, senior management entrusted by its shareholders and board of directors. IMSS provides social security to over 71 Million people nationwide in Mexico. The purpose of the pilot for the public health authority is to collect evidence such as avoidance of blindness of at least 95% of diabetics' cases, avoid wrong referral of patients to the specialist, time reduction for an appointment to the specialist within the following 48 hours (instead of 8 months), control and monitor of diabetics, provide a solid database, unburden diabetes costs which nowadays surpass $ 96 Million Mexican pesos per day (approx. $ 4.6 Million US dollars), among others. As well specialists and observers of the pilot will certify CARA's performance for automatic detection, biometrics and telemedicine friendly connectivity, by accessing randomly to patients' results. In the automatic detection the specialists will provide feedback in terms of sensitivity and specificity minding that DIAGNOS has quality certifications and approvals from COFEPRIS in Mexico, FDA in the US, Health Canada, to mention a few. In biometrics and telemedicine friendly connectivity, the specialists will look after its integration to IMSS Digital program on how doctors and patients interact by safeguarding the management of information. "DIAGNOS is proud to collaborate with IMSS for a pilot starting at World Diabetes Day: in 3 weeks we'll screen patients within 2 family medicine units (UMF) of IMSS' first level of attention. Both parties are investing time and resources to run successfully run it in order to set the principles for a strategic alliance by fitting DIAGNOS' Wellness Program powered by our CARA platform into IMSS' flagship diabetes programs: DiabetIMSS and PrevenIMSS. We're confident that the outcome of this pilot will be beneficial for the Mexican diabetics entitled with social security coverage within the national territory," said André Larente, President of DIAGNOS. Mr. Larente also added "Our health IT technology was made to be accessible to all people around the world with diabetes or pre-diabetes condition, our vision is to provide universal coverage and we keep our efforts every day to achieve it". After gathering conclusions from the pilot, IMSS will evaluate the feasibility for a multi-annual contract starting in 2017 with different business models: fix in clinics, mobile and the ignition of the National Ophthalmology Centre in order to provide specific eye care to a minimum of 1.5 to 5 Million diabetics. Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources. CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union. This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, please contact DIAGNOS, visit our website at www.diagnos.com, or visit the SEDAR website at www.sedar.com.


After several decades without any notable progress, there are encouraging results in research and development of anti-TB drugs, the result of a large number of projects now in competition. Along with developing new drugs to treat tuberculosis (TMC207, SQ109, LL3858) are being reassessed others to optimize their effectiveness in order to shorten and simplify therapy (rifampin and rifapentine) and three other drugs, currently used for other indications, were forwarded towards TB (gatifloxacin and moxifloxacin, linezolid). Time to approval as a antiTB drug is 10-15 years, consisting of phases of preclinical and clinical research. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis resulted in a small but statistically nonsignificant increase in 8 th-week culture negativity. TMC207, a diarylquinoline with a unique way to address Mycobacterial ATP synthetase, shows high activity in vitro against Mycobacterial strains sensitive or resistant to all drugs in the first and second line, including fluoroquinolones, demonstrating exceptional qualities in vivo against several species of mycobacteria, in various animal models. TMC207 was added to a basic standard regimen in a study of MDR-TB patients. After two months and satisfactory tolerability, sputum conversion rate in culture was 48% (vs 9% in the placebo group). Two nitroimidazole (PA-824 and OPC-67683) are currently in clinical development. PA-824 demonstrated good safety and tolerability in adult patients with pulmonary TB in South Africa, when given once daily for 7 days. Associating isoniazid, would prevent the selection of mutants resistant to Isoniazid. Linezolid 600 mg is currently being tested in a Phase II for treatment of XDR-TB in the Republic of Korea. PNU-100480, analogous to the previous one, has the potential to significantly shorten the treatment in cases where there is sensitivity and in those with resistance to drugs. 300 mg dose is under investigation in a phase II pilot study in MDR-TB in South Africa. With this interest and commitment, it appears that there is a chance of having a new drug available soon.

Loading UMF collaborators
Loading UMF collaborators